QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (REVIEW)
https://doi.org/10.15372/SSMJ20190108
Abstract
The target drugs use showed high efficiency and raised the patients’ life expectancy approaching it to average on population and became the new era in hematooncology. Given the currant tendency, the investigation of problems of patients’ quality of life and the affecting factors is actual. We have analyzed the modern foreign and domestic literature data concerning the quality of life of patients with myeloproliferative diseases and their variation principal causes and parameters reflecting the phenomenon. Also, we state the basic information on diseases where the myeloid lineage hyperplasia is the root cause. The pathophysiological and clinical features of the blood system pathologies are specified. The high-priority factors influencing quality of life of patients with myeloproliferative diseases are highlighted. The basic mechanisms of cardiovascular and thrombotic events development, playing a key role in the patients quality of life forming are in more detail described on the example of chronic myeloid leukemia and polycythemia vera. Moreover, the expediency of search of new diagnostic approaches to the assessment of myeloproliferative diseases course and the patients’ quality of life on a background of modern therapy have been shown.
About the Authors
I. L. Davydkin
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Igor Leonidovich DAVYDKIN – doctor of medical sciences, professor, vice rector for research and innovation technology, head of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
N. S. Popelnyuk
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Natalya Sergeevna POPELNYUK – candidate of medical sciences, assistant of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
K. V. Naumova
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Kseniya Viktorovna NAUMOVA – postgraduate student of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
E. V. Mordvinova
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Elizaveta Vladimirovna MORDVINOVA – medical resident of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
T. Yu. Stepanova
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Tatyana Yurevna STEPANOVA – candidate of medical sciences, associate professor of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
S. P. Krivova
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Svetlana Petrovna KRIVOVA – candidate of medical sciences, associate professor of the chair of hospital therapy with courses of outpatient therapy and transfusiology
443099, Samara, Chapayevskaya str., 89
A. A. Rogozina
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Anastasiya Aleksandrovna ROGOZINA – student of department of general medicine
443099, Samara, Chapayevskaya str., 89
T. P. Kuzmina
Samara State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Tatyana Pavlovna KUZMINA – medical resident
443099, Samara, Chapayevskaya str., 89
References
1. Abdulkadyrov K.M., SHuvaev V.A., Martynkevich I.S. What do we know about polycythemia vera (review and own data). Onkogematologiya = Oncohematology. 2015. 10. (3). 28-42. [In Russian].
2. Abelsson J., Andréasson B., Samuelsson J., Hultcrantz M., Ejerblad E., Johansson B., Emanuel R., Mesa R., Johansson P. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms // Leuk. Lymphoma. 2013. 54. (10). 2226–2230.
3. Anderson K.R., Chambers C.R., Lam N., Yau P.S., Cusano F., Savoie M.L., Sheikh N.Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia // J. Oncol. Pharm. Pract. 2015. 21. (1). 19–25.
4. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., Bloomfield C.D., Cazzola M., Vardiman J.W. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. 2016. 127. (20). 2391-2405.
5. Ault P., Kantarjian H., O’Brien S., Faderl S., Beran M., Rios M.B., Koller C., Giles F., Keating M., Talpaz M., Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib // J. Clin. Oncol. 2006. 24. (7). 1204–1208.
6. Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., ApperleyJ.F., Cervantes F., Clark R.C., Cortes J.E., Guilhot F., Hjorth-Hansen H., Hughes T.P., Kantarjian H.P., Dong-Wook Kim, Larson R.A., Lipton J.H., François-Xavier Mahon, Martinelli G., Mayer J., Müller M.C., Niederwieser D., Pane F., Radich J.P., Rousselot P., Saglio G., Saußele S., Schiffer C., Silver R., Simonsson B., Steegmann J., Goldman J.M., Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 // Blood. 2013. 122. (6). 872–884.
7. Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H.C., Hehlmann R., Hoffman R., Kiladjian J., Kröger N., Mesa R., McMullin M.F., Pardanani A., Passamonti F., Vannucchi A.M., Reiter A., Silver R.T., Verstovsek S., Tefferi A. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet // J. Clin. Oncol. 2011. 29. (6). 761-770.
8. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., Ruggeri M., Rodeghiero F., Randi M.L., Bertozzi I., Gisslinger H., Buxhofer-Ausch V., Stefano V., Betti S., Rambaldi A., Vannucchi A.M., Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) // Blood. 2012. 120. (26). 5128-5133.
9. Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E., McMullin M.F., Passamonti F., Vannucchi A.M., Besses C., Gisslinger H., Samuelsson J., Verstovsek S., Hoffman R., Pardanani A., Cervantes F., Tefferi A., Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project// Blood. 2013. 121. (23). 4778-4781.
10. Breccia M., Efficace F., Sica S., Abruzzese E., Cedrone M., Turri D., Gobbi M., Carella A.M., Gozzini A., Usala E., Cavazzini F., Danise P., Tiribelli M., Binotto G., Pregno P., Bocchia M., Gaidano G., Crugnola M., Bonifacio M., Avanzini P., Celesti F., Guella A., Martino B., Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E., Gambacorti-Passerini C., Alimena G. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients // Leuk. Res. 2015. 39. (10). 1055–1059.
11. Chen T.C., Chen L.C., Huang Y.B., Chang C.S. Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan // Int. J. Clin. Pharm. 2014. 36. (1). 172–181.
12. Clark C.E., Taylor R.S., Shore A.C., Ukoumunne O.C., Campbell J.L. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis // Lancet. 2012. 379. (9819). 905-916.
13. Davydkin I. L., Kondurcev V. A., Stepanova T. Yu., Bobylev S. A. Fundamentals of hemostasis: monograf. Samara: Ofort, 2009. 436 p. [In Russian].
14. Demidova A.V., Volkova M.A. Polycythemia vera. Clinical oncohematology. Moscow: Meditsina, 2001. 576 p. [In Russian].
15. Evsina O.V. Quality of life in medicine – important factor of patient health status (literature review). Lichnost' v menyayushchemsya mire: zdorov'e, adaptaciya, razvitie = Personality in changing world: health, adaptation, development. 2013. 1. (1). 119-133. [In Russian].
16. Finazzi, G., Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia // Leukemia. 2008. 22. (8). 1494-1502.
17. Flynn K.E., Atallah E. Quality of life and long term therapy in patients with chronic myeloid leukemia // Curr. Hematol. Malig. Rep. 2016. 11. (2). 80–85.
18. Gorokhovskaya G.N., Hejlo T.S., Martynov A.I. Microcirculation in patients with arterial hypertension while they suffer from polycythemia vera. Mezhdunarodnyy zhurnal po immunoreabilitatsii = International journal of immunorehabilitation. 2001. 3. (l). 48-49. [In Russian].
19. Guerin A., Chen L., Ionescu-Ittu R., Marynchenko M., Nitulescu R., Hiscock R., Keir C., Wu E.Q. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase // Curr. Med. Res. Opin. 2014. 30. (11). 2317–2328.
20. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance // Health Qual. Life Outcomes. 2006. 4. 79.
21. Hamerschlak N., de Souza C., Cornacchioni A.L., Pasquini R., Tabak D., Spector N., Steagall M. Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor // Support. Care Cancer. 2014. 22. (8). 2113–2118.
22. Hirji I., Gupta S., Goren A., Chirovsky D.R., Moadel A.B., Olavarria E., Victor T.W., Davis C.C. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective // Health Qual. Life Outcomes. 2013. 11. (1). 167.
23. Höglund M., Sandin F., Hellström K., Björeman M., Björkholm M., Brune M., Dreimane A., Ekblom M., Lehmann S., Ljungman P., Malm C., Markevärn B., Myhr-Eriksson K., Ohm L., Olsson-Strömberg U., Själander A., Wadenvik H., Simonsson B., Stenke L., Richter J.Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry // Blood. 2013. 122. (7). 1284–1292.
24. Ionova T., Nikitina T., Lomaia E., Kuchma G., Machyulaytene E., Usacheva E., Shnaider T., Rodionova A., Kurbatova K. Quality of life and symptom profile in patients with Imatinib-resistant or intolerant chronic myeloid leukemia // Haematologica. 2012. 97. (1). 249.
25. Ionova T.I., Nikitina T.P., Lomaia E.G., Kuchma G.B., Machyulajtene E.R., Usachyova E.I., SHnejder T.V., Rodionova A.YU., Kurbatova K.A. Factors of life quality, area of symptoms and clinical effect from the second line dazatinib therapy in patients with resistant form of chronic myeloid leukemia or imatinib intolerance: results of the second-year monitoring survey. Onkogematologiya = Oncohematology. 2015. 10. (3). 18-27. [In Russian].
26. Kolesnikova I., Roitman E., Roumyantsev S., Ershova L., Roumiantseva J. Hemorheologic disturbances is venous thromboembolism risk factor in children with acute lymphoblastic leukemia (pilot study) // Thromb. Res. 2014. 133. (S3). 35-123.
27. Kwaan, H. C. Hyperviscosity in polycythemia vera and other red cell abnormalities // Semin. Thromb. Hemost. 2003. 29. (5). 451-458.
28. Landoli R., Gennaro L., Barbui T., Stefano V., Finazzi G., Marfisi R.M., Tognoni G., Marchioli R. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera // Blood. 2007. 109. (6). 2446-2452.
29. Lebedeva P.A. Endothelial dysfunction and arterial hypertension. Samara: Ofort, 2010. 192 p. [In Russian].
30. Marchioli R., Finazzi G., Specchia G., Arianna Masciulli A., Mennitto M. R., Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera // Thrombosis. 2011. 2011. (1). 1-9.
31. Mauro M.J., Davis C., Zyczynski T., Khoury H.J. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia // Ther. Adv. Hematol. 2015. 6. (1). 3–14.
32. Melikayn A.L., Turkina A.G., Kovrigina A.M., Subortseva I.N.,Sudarikova A.B., Sokolova M.A., Zaritskiy A.Yu., Lomaia E.G., Shuvaev V.A., Gritsaev S.V., Martynkevich I.S., Afanasiev B.V., Morozova E.V., Baykov V.V., Golenkov A.K., Ivanova V.L., Kaplanov K.D., Pospelova T.I., Ageeva T.A., Shatokhin Yu.V., Savchenko V.G. Clinical recommendations for diagnosis and therapy of ph-negative myeloproliferative neoplasms (polycythemia vera, essential trombocythemia, primary myelofibrosis) (Edition 2016). Gematologiya i transfuziologiya = Gematology and Transfusiology. 2017. 62. (S1). 25-60. [In Russian].
33. Mesa R.A, Niblack J., Wadleigh M., Verstovsek S., Camoriano J., Barnes S., Tan A.D., Atherton P.J., Sloan J.A., Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) // Cancer. 2007. 109. (1). 68-76.
34. Mesa R.A, Scherber R.M, Geyer H.L. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors // Leuk. Lymphoma. 2015. 56. (7). 1989-1999.
35. Myasoedova N.A., Thostova EH.B., Belousov YU.B. Estimation of life quality of patients who has different cardiovascular diseases. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2002. 4. (1). 53-57. [In Russian].
36. Noens L., van Lierde M.A., De Bock R, Verhoef G., Zachee P., Berneman Z., Martiat P., Mineur P., Van Eygen K., MacDonald K., De Geest S., Albrecht T., Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study// Blood. 2009.113. (22). 5401–5411.
37. Pye S.M., Cortes J., Ault P., Hatfield A., Kantarjian H., Pilot R., Rosti G., Apperley J.F.The effects of imatinib on pregnancy outcome// Blood. 2008. 111. (12). 5505–5508.
38. Rybas A.V. Polycythemiya nera. Vestnik molodogo uchenogo = Journal of young scientist. 2016. 3. 19-25. [In Russian].
39. Saussele S., Krauss M.P., Hehlmann R., Lauseker M., Proetel U., Kalmanti L., Hanfstein B., Fabarius A., Kraemer D., Berdel W.E., Bentz M., Staib P., de Wit M., Wernli M., Zettl F., Hebart H.F., Hahn M., Heymanns J., Schmidt-Wolf I., Schmitz N., Eckart M.J., Gassmann W., Bartholomäus A., Pezzutto A., Leibundgut E.O., Heim D., Krause S.W., Burchert A., Hofmann W.K., Hasford J., Hochhaus A., Pfirrmann M., Müller M.C. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV // Blood. 2015.126. (1). 42–49.
40. Scherber R., Dueck A.C. Johansson P., Barbui T., Barosi G., Vannucchi A.M., Passamonti F., Andreasson B., Ferarri M.L., Rambaldi A., Samuelsson J., Birgegard G., Tefferi A., Harrison C.N., Radia D., Mesa R.A. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients // Blood. 2011. 118. (2). 401-408.
41. Shihbabaeva D.I., Shuvaev V.A., Martynkevich I.S., Abdulkadyrov K.M., Zotova I.I., Udal'eva V.YU., Fominyh M.S., Zamotina T.B., Polushkina L.B. Their own experience of observation and treatment of patients with polycythemia vera. Vestnik gematologii = Hematology bulletin. 2015. 11. (4). 13-20. [In Russian].
42. Siegel F.P., Tauscher J., Petrides P.E. Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients // Am. J. Hematol. 2013. 88. (8). 665-669.
43. Smith B.D. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects // J. Natl. Cancer Inst. 2011. 103. (7). 527–529.
44. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management // Am. J. Hematol. 2012. 87. (3). 285-293.
45. Tyukina Yu.V., Lodygina T.I. Rate of vascular events in patients with polycythemia vera. Byulleten' Severnogo gosudarstvennogo medicinskogo universiteta = Bulletin of the Northern state medical university. 2011. (1). 141-142. [In Russian].
46. Unnikrishnan R., Veeraiah S., Mani S., Rajendranath R., Rajaraman S., Vidhubala Elangovan G.S., Radhakrishnan V., Ganesan T.S., Sagar T.G., Ganesan P. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib // Clin. Lymphoma Myeloma Leuk. 2016. 16. (6). 366–371.
47. Vayá A. Suescun M. Hemorheological parameters as independent predictors of venous thromboembolism // Clin. Hemorheol. Microcirc. 2013. 53. (1-2). 131-141.
48. Venegoni P., Cyprus G. Polycythemia and the heart. A review // Tex. Heart Inst. J. 1994. 21. (1). 198-201.
49. Volkova M.A. Clinical oncohematology. Moscow: Meditsina, 2007. 1144 p. [In Russian].
50. Vorob'ev A.I., Al'-Radi L.S., Andreeva N.E. Rational pharmacotherapy of blood disorders. Moscow: Litterra, 2009. 688 p. [In Russian].
51. Zav'yalova A. I. Policitemia vera and arterial hypertension or painless myocardial ischemia. Abstract of thesis….cand. med. sciences. Moscow, 2006. [In Russian].
Review
For citations:
Davydkin I.L., Popelnyuk N.S., Naumova K.V., Mordvinova E.V., Stepanova T.Yu., Krivova S.P., Rogozina A.A., Kuzmina T.P. QUALITY OF LIFE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (REVIEW). Сибирский научный медицинский журнал. 2019;39(1):58-65. (In Russ.) https://doi.org/10.15372/SSMJ20190108
Views:
3603
Email this article 